Mosapramine

Overview

Mosapramine (Clospipramine) is an orally active antipsychotic agent and one of the metabolites of Clocapramine ( HY-B2073 ) after oral absorption. Mosapramine exerts its effects by specifically binding to striatal dopamine D2 receptors and frontal lobe 5-HT2 receptors, with a D2/5-HT2 receptor occupancy ratio of 7.4. Mosapramine induces typical neuropharmacological responses in rat brain regions, including extrapyramidal symptoms, hyperprolactinemia, increased salivation, constipation, and upregulated Fos protein expression. Mosapramine also features a reduced incidence of weight loss. Mosapramine is applicable to research related to schizophrenia.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Schizophrenia | Products > Signaling Pathways > Others | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Drug Derivative | Products > Signaling Pathways > Dopamine Receptor | Products > Signaling Pathways > 5-HT Receptor

Product Information

• Catalog No.: HY-106584
• CAS No.: 89419-40-9
• Molecular Formula: C28H35ClN4O
• Molecular Weight: 479.06
• Purity: 98.58%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (5.22 mM); Clear solution
• Availability: In-stock

Source

Original product source